Trump's Drug Pricing Strategy Should Target Foreign Free-Riding, Not Domestic Price Controls
Source: "Trump's prescription drug deals should target foreign price controls | Fox News." September 21, 2026. www.foxnews.com
The Gist
The author argues that instead of squeezing drug companies or capping U.S. prices, Trump should pressure other rich countries like Germany, Japan, and the UK to pay more for the medicines they already benefit from. The idea is that Americans are unfairly footing most of the bill for drug research, and if other wealthy nations paid their fair share, U.S. drug prices could come down without hurting innovation.
Conclusion
The Trump administration should redirect its drug pricing negotiation strategy away from pressuring U.S. drugmakers and domestic price mandates, and instead focus on forcing wealthy foreign countries to pay more for pharmaceuticals, in order to lower U.S. drug prices without harming biomedical innovation.
Premises
- Wealthy foreign governments (Germany, Japan, France, Switzerland, UK) use price controls, mandatory rebates, and reimbursement delays to suppress what they pay for innovative medicines.
- American patients account for roughly three-quarters of pharmaceutical profits and over half of global R&D spending, a share disproportionate to America's share of the world economy.
- Domestic policies like 'most-favored-nation' pricing would tie U.S. prices to artificially low foreign prices, effectively importing foreign price controls and reducing R&D funding, jobs, and competitiveness against China.
- The Trump administration has already demonstrated success with this approach, securing a deal requiring the UK to raise drug payments by 25%.
- The administration is applying similar pressure to Germany via a formal trade investigation into its price controls.
- If other developed countries paid U.S. prices for new drugs, global pharmaceutical revenue would rise by more than $254 billion, which could fund an R&D boom benefiting American patients and jobs.
Assumptions
- Foreign governments have the willingness and political capacity to substantially raise what they pay for pharmaceuticals under U.S. pressure.
- Increased foreign payments would translate into increased R&D investment and lower U.S. prices rather than simply increased pharmaceutical company profits.
- The current disproportionate U.S. share of R&D funding is primarily caused by foreign free-riding rather than other factors (e.g., U.S. market structure, insurance systems, lack of domestic price negotiation).
- Diplomatic/trade pressure is a more effective and sustainable tool than domestic price regulation for lowering costs.
- The $254 billion analysis accurately predicts real-world revenue and R&D outcomes if foreign prices rose to U.S. levels.